Pyroptosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pyroptosis is a highly inflammatory form of regulated cell death mediated by the gasdermin family of pore-forming proteins. Distinguished from apoptosis, which is immunologically silent, and necroptosis, which depends on RIPK3/MLKL signaling, pyroptosis is characterized by inflammasome activation, [caspase]-1 or caspase-11/4/5 cleavage of gasdermin D (GSDMD), plasma membrane pore formation, cell swelling, and the release of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) 1(https://www.nature.com/articles/s41392-024-01958-2). The term "pyroptosis" derives from the Greek roots pyro (fire/fever) and ptosis (falling), reflecting its inflammatory nature (Shi et al., 2015) [1].
Emerging evidence implicates pyroptosis in the pathogenesis of multiple [neurodegenerative /diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, including [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, and [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--. Pyroptotic cell death in the central nervous system is predominantly executed by [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- (Lu et al., 2025) [2].
The canonical pyroptosis pathway is initiated by the assembly of inflammasome complexes, multi-protein platforms that activate caspase-1 3(https://www.nature.com/articles/s41423-025-01275-w) (Flores et al., 2018):
- Pattern recognition: Intracellular sensors detect danger-associated molecular patterns (DAMPs) such as [amyloid-β ([Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- aggregates, misfolded [α-synuclein/proteins/alpha, or [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
- Inflammasome assembly: The sensor protein (e.g., [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX--, NLRP1, AIM2, or NLRC4) oligomerizes and recruits the adaptor ASC (apoptosis-associated speck-like protein containing a CARD)
- Caspase-1 activation: Pro-caspase-1 is recruited to the inflammasome via CARD-CARD interactions and undergoes proximity-induced autoproteolytic activation
- GSDMD cleavage: Active caspase-1 cleaves GSDMD between its autoinhibitory C-terminal domain (GSDMD-CT) and pore-forming N-terminal domain (GSDMD-NT)
- Pore formation: GSDMD-NT oligomerizes into ring-shaped pores (~18 nm inner diameter) in the plasma membrane
- Cytokine release and cell lysis: IL-1β and IL-18 are released through GSDMD pores; sustained pore formation causes osmotic lysis
The non-canonical pathway is triggered by cytosolic lipopolysaccharide (LPS) and involves caspase-11 (mouse) or caspase-4/5 (human) 1(https://www.nature.com/articles/s41392-024-01958-2):
- Caspase-11/4/5 directly binds intracellular LPS via its CARD domain
- Activated caspase-11/4/5 cleaves GSDMD, inducing pore formation
- Secondary [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- activation occurs via potassium efflux through GSDMD pores
- This pathway is particularly relevant in gram-negative bacterial infections and sepsis-associated neuroinflammation
The gasdermin superfamily includes six members in humans, each with distinct tissue expression and activation mechanisms 4(https://www.nature.com/articles/s41419-025-08373-7):
| Gasdermin |
Activating Protease |
Expression in CNS |
Relevance |
| GSDMA |
Granzyme A |
Limited |
Skin diseases |
| GSDMB |
Granzyme A, Caspase-1 |
Low |
Autoimmunity |
| GSDMC |
Caspase-8 |
Low |
Cancer |
| GSDMD |
Caspase-1, -4, -5, -11 |
[microglia[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/astrocytes |
Primary CNS pyroptosis executor |
| GSDME |
Caspase-3 |
[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- |
Secondary pyroptosis/necrosis |
| PJVK |
Unknown |
Inner ear |
Hearing loss |
GSDMD is the primary executor of pyroptosis in the brain, expressed predominantly in [microglia[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/astrocytes. GSDME is notable because caspase-3 cleavage can convert apoptosis to pyroptosis in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, potentially contributing to inflammatory neuronal death link (Wu et al., 2024) [3].
Pyroptosis plays a significant role in the neuroinflammatory cascade of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. The [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome] is a central mediator 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC11090449/) (Han et al., 2024):
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---triggered microglial pyroptosis: Aggregated [amyloid-β[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- activates the [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome in [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia, leading to caspase-1-dependent GSDMD cleavage and release of IL-1β and IL-18. This reduces microglial phagocytic capacity for [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance, perpetuating a vicious cycle of plaque accumulation and neuroinflammation
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX---induced pyroptosis: Hyperphosphorylated tau] aggregates also activate [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX---mediated pyroptosis. GSDMD protein levels increase alongside reactive microglial morphology in tauopathy mouse models link
- Neuronal NLRP1 inflammasome: In contrast to microglial [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX--, the NLRP1 inflammasome mediates neuronal pyroptosis in AD, directly contributing to neuronal loss
- Peripheral GSDMD activation: Myeloid GSDMD drives early peripheral inflammation in AD, with GSDMD deficiency impairing T-cell activation and preventing T-cell infiltration into the brain 6(](https://link.springer.com/article/10.1186/s12974-024-03255-9)
Misfolded [α-synuclein/proteins/alpha activates the [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome in both [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia and [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, initiating pyroptosis link (Li et al., 2025):
- GSDMD acts as a pyroptosis executor contributing to glial reaction and dopaminergic neuronal death
- Ablation of GSDMD attenuates [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- damage by reducing dopaminergic neuronal death, microglial activation, and detrimental transformation
- dopamine neuron loss in the substantia nigra is accompanied by elevated expression of pyroptosis markers including [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX--, ASC, activated caspase-1, cleaved GSDMD, IL-18, and IL-1β
- α-Synuclein fibrils trigger both the canonical (caspase-1) and non-canonical (caspase-11) inflammasome pathways
Robust GSDMD activation has been observed in [ALS[/diseases/[als[/diseases/[als[/diseases/als--TEMP--/diseases)--FIX-- spinal cords 8(:
- [SOD1/proteins/sod1-mutant motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- show elevated expression of GSDMD in spinal cord [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--:
The concept of PANoptosis describes the simultaneous activation of pyroptosis, apoptosis, and necroptosis through the PANoptosome, a multiprotein complex containing components from all three pathways. In the CNS, PANoptosis may explain why inhibiting a single death pathway often fails to protect [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- [4].
Caspase-3 cleavage of GSDME can convert apoptotic cell death to pyroptotic cell death in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, amplifying the inflammatory response. This is particularly relevant when:
- [Caspase]-3 is activated during apoptosis in GSDME-expressing [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Insufficient phagocytic clearance allows secondary necrosis
ferroptosis and pyroptosis share upstream regulators including reactive oxygen species and iron metabolism. Mitochondrial [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- generated during ferroptotic stress can activate [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX--, linking iron-dependent lipid peroxidation to inflammasome-driven pyroptosis [5].
Inhibiting pyroptosis represents an emerging therapeutic strategy for neurodegenerative diseases:
- MCC950 (CRID3): Selective [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inhibitor that blocks ASC oligomerization; reduces neuroinflammation and amyloid pathology in AD mouse models
- OLT1177 (dapansutrile): Oral [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inhibitor in clinical trials for inflammatory conditions
- CY-09: Inhibits [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- ATPase activity
- VX-765 (belnacasan): Selective caspase-1 inhibitor that reduces [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- deposition and improves cognition in AD mouse models
- VX-740 (pralnacasan): Earlier-generation caspase-1 inhibitor
- Disulfiram: FDA-approved drug for alcohol use disorder that covalently modifies GSDMD Cys191, preventing pore formation
- Necrosulfonamide (NSA): Directly binds GSDMD-NT to block pore assembly
- Dimethyl fumarate (DMF): Succinates GSDMD at Cys191
Recent studies suggest combination therapy targeting both GSDMD and immune checkpoint pathways. GSDMD inhibition combined with anti-PD-1 antibody synergistically reduced T-cell-mediated neuroinflammation in AD models 6(https://link.springer.com/article/10.1186/s12974-024-03255-9) [6].
¶ Detection and Biomarkers
Pyroptosis can be detected and monitored through several approaches:
- GSDMD-NT levels: Cleaved GSDMD N-terminal domain as a direct indicator of pyroptosis activation
- IL-1β and IL-18: Elevated cytokine levels in [cerebrospinal fluid (CSF)[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX-- or plasma
- ASC specks: Detectable in CSF as indicators of inflammasome activation
- Caspase-1 activity: Fluorescent substrate-based assays (FLICA)
- [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--: Elevated levels may reflect astrocytic pyroptosis
- [Csf Biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX--
- [All Mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Pyroptosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Rao Z, Zhu Y, Yang P, et al. (2024]. Pyroptosis in health and disease: mechanisms, regulation and clinical perspective. Signal Transduction and Targeted Therapy, 9, 245. DOI)
- [Han X, Xu T, Fang Q, et al. (2024]. [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX--/1-mediated pyroptosis: beneficial clues for the development of novel therapies for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Neural Regeneration Research, 19(11), 2400–2410. [PMC)(https://pmc.ncbi.nlm.nih.gov/articles/PMC11090449/)
- [Lu Y, Li Y, Bhatt S, et al. (2025]. [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome in neuroinflammation and central nervous system diseases. Cellular & Molecular Immunology, 22, 341–355. [DOI)(https://www.nature.com/articles/s41423-025-01275-w)
- [Chen Y, Bhatt S, et al. (2025]. Gasdermins in neurodegeneration: emerging mechanisms and therapeutic targets. Cell Death & Disease, 16, 145. DOI)
- [Li W, Chen W, et al. (2025]. GASDERMIN D-mediated pyroptosis as a therapeutic target in TAU-dependent Frontotemporal Dementia mouse model. Journal of Biomedical Science, 32, 28. DOI)
- [Chen X, Bhatt S, et al. (2024]. Myeloid gasdermin D drives early-stage T cell immunity and peripheral inflammation in a mouse model of Alzheimer's Disease. Journal of neuroinflammation, 21, 290. DOI)
- [Wu Y, Li Q, et al. (2024]. Pyroptosis-mediator GSDMD promotes [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- pathology via microglial activation and dopaminergic neuronal death. Brain, Behavior, and Immunity, 121, 45–58. [DOI)(https://www.sciencedirect.com/science/article/abs/pii/S0889159124003192)
- [Johnson A, et al. (2025]. Gasdermin D is activated but does not drive neurodegeneration in SOD1G93A model of ALS: Implications for targeting pyroptosis. Neurobiology of Disease, 207, 106799. PMC)
- [Shi J, Zhao Y, Wang K, et al. (2015]. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature, 526(7575), 660–665. DOI
- DOI
- [Voet S, Srinivasan S, Lamkanfi M, van Loo G. (2019]. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Molecular Medicine, 11(6), e10248. DOI
- [Flores J, Noël A, Bhatt S, et al. (2018]. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's Disease mouse model. Nature Communications, 9, 3916. DOI
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
12 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 39%